The U.S. Food and Drug Administration (FDA) has approved vismodegib (Erivedge™, Roche/Genentech), the first medicine for adults with a type of skin cancer, called advanced or metastatic basal cell carcinoma or BCC, that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. The new drug is a first-in-class Hedgehog Pathway…
Search Medpedia News & Analysis
More from this contributor
- Blinatumomab Achieved High Rate ...
- Fidaxomicin Offers Faster Diarrh...
- Rilotumumab Moves into Phase III...
- Study Shows ImmunoSEQ Assay Sign...



Comments
To add a comment to the original post, click here.
You must be signed in to post a comment.
Sign in nowThere are no comments for this post.